

**Supplementary Table 3.** The safety profile of each treatment regimen

Variable	Quadruple therapy ( <i>n</i> = 50)	GLP-1RA therapy ( <i>n</i> = 46)
Hypoglycemia	3 (6.0)	2 (4.3)
Infection including UTI, genital		
Male	0	0
Female	1 (2.0)	0
DKA	0	0
Weight concerns (subjective)	1 (2.0)	0
Gastrointestinal troubles	1 (2.0)	6 (13.0)

Values are presented as number (%).

GLP-1RA, glucagon-like peptide-1 receptor agonist; UTI, urinary tract infection; DKA, diabetic ketoacidosis.